Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 15/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.70 |
| ▸ | HTR2C | P28335 | 3/20 | 0.60 |
| ▸ | HTR2B | P41595 | 2/20 | 0.60 |
| ▸ | HTR6 | P50406 | 1/20 | 0.55 |
| ▸ | PNMT | P11086 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7855779 | 0.92 | MLNR (0.63) | MLNRCYP2D6HTR2CHTR2BPNMT | |
| SCHEMBL12608373 | 0.81 | HRH3 (0.51) | MLNRCYP2D6HTR2CHTR6 | |
| SCHEMBL19990835 | 0.81 | MLNR (0.51) | MLNRCYP2D6HTR2CHTR2BHTR6 | |
| SCHEMBL12651580 | 0.80 | MLNR (0.50) | MLNRCYP2D6 | |
| SCHEMBL20097742 | 0.78 | DRD1 (0.49) | MLNRCYP2D6HTR2CHTR6 | |
| SCHEMBL19377471 | 0.77 | MLNR (0.53) | MLNRCYP2D6HTR2CHTR2BHTR6 | |
| SCHEMBL19377470 | 0.77 | MLNR (0.53) | MLNRCYP2D6HTR2CHTR2BHTR6 | |
| SCHEMBL7860146 | 0.76 | MLNR (0.51) | MLNRCYP2D6HTR2CHTR2BHTR6 | |
| SCHEMBL5455774 | 0.75 | HTR2C (1.00) | HTR2CHTR2BHTR6PNMT | |
| SCHEMBL1787913 | 0.75 | HRH3 (0.57) | MLNRCYP2D6HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326625-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| WO-2010007382-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | HRH4, HRH3, HRH2 | MLNR 1126/4885CYP2D6 359/4885HTR2C 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.